share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

SEC announcement ·  Mar 22 17:48
Summary by Moomoo AI
CRISPR Therapeutics AG's Chief Executive Officer, Samarth Kulkarni, has engaged in a transaction involving the company's stock on March 20, 2024. The details of the transaction, including the number of shares involved and the transaction price, have not been disclosed in the announcement. The action reflects the CEO's dealings with the company's non-derivative securities. Investors are advised to note the involvement of a high-level executive in the company's stock transactions, which may be indicative of the company's internal confidence and future prospects.
CRISPR Therapeutics AG's Chief Executive Officer, Samarth Kulkarni, has engaged in a transaction involving the company's stock on March 20, 2024. The details of the transaction, including the number of shares involved and the transaction price, have not been disclosed in the announcement. The action reflects the CEO's dealings with the company's non-derivative securities. Investors are advised to note the involvement of a high-level executive in the company's stock transactions, which may be indicative of the company's internal confidence and future prospects.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more